This week two new articles about #BC007 were published where managers from @BerlinCures talk about the company’s planned steps and studies for #LongCOVID for this year and 2023.
In this thread is a short summary.
In this thread is a short summary.
According to one new interview BerlinCures has now collected the necessary funds for a Phase II study with #BC007 for #LongCOVID.
The number of participants will be significantly higher than 100.
The number of participants will be significantly higher than 100.
BerlinCures wants to submit the Clinical Trial application in the upcoming weeks.
Results from this study are expected in August-December 2023.
Results from this study are expected in August-December 2023.
When #BC007 will become available seems to be dependant on whether there has to be a Phase III study. The other option would be an emergency approval based on the Phase II study. That has to be decided by the responsible authorities.
If #BC007 successfully passes a Phase III study the drug would be available „at the end of 2023 at the earliest, realistically in 2024”.
BerlinCures is also still looking for investors.
According to two interviewed co-owners an established pharma company should take the lead if the upcoming studies are successful, for example via a licensing agreement, a partnership or a complete takeover.
According to two interviewed co-owners an established pharma company should take the lead if the upcoming studies are successful, for example via a licensing agreement, a partnership or a complete takeover.
These are the two new articles.
faz.net/aktuell/wirtsc…
watson.ch/international/…
The first one is also available in Spanish.
news.eseuro.com/coronavirus/10…
faz.net/aktuell/wirtsc…
watson.ch/international/…
The first one is also available in Spanish.
news.eseuro.com/coronavirus/10…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
